An update from Kazia Therapeutics ( (KZIA) ) is now available.
On March 31, 2025, Kazia Therapeutics announced the sale of its intellectual property and trademark rights for the oncology drug candidate Cantrixil to Vivesto for USD $1 million. This transaction provides Kazia with non-dilutive funding to support its clinical-stage pipeline. Vivesto, which had previously licensed the global development rights for Cantrixil in March 2021, is now exploring its use in hematological cancers rather than ovarian cancer. This strategic move allows Kazia to focus resources on its other promising drug candidates, potentially impacting its market positioning and stakeholder interests.
More about Kazia Therapeutics
Kazia Therapeutics Limited is an oncology-focused drug development company based in Sydney, Australia. The company is primarily engaged in developing investigational drugs for the treatment of various forms of brain cancer, with its lead program being paxalisib, a brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway. Kazia is also working on EVT801, a small molecule inhibitor of VEGFR3, which has shown promise in preclinical studies.
YTD Price Performance: -49.57%
Average Trading Volume: 2,021,765
Technical Sentiment Signal: Buy
Current Market Cap: $4.92M
For an in-depth examination of KZIA stock, go to TipRanks’ Stock Analysis page.